George Yesenosky, MD
Clinical Cardiac Electrophysiology · Philadelphia, PANPI 1265408470
Payments from drug & device makers
Across 459 payments — averaging $161.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Impulse Dynamics (USA) Inc.$32K
- Boston Scientific$25K
- Abbott$5K
- Medtronic$4K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
- Atricure, Inc.$1K
- plus $5K from 29 others
What the payments were for
- Consulting fees$28,25638%
- Speaking & faculty fees$23,00031%
- Travel & lodging$8,23511%
- Food & beverage$14,85120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Impulse Dynamics (USA) Inc. | 63 | $32,170 |
| Boston Scientific | 123 | $24,522 |
| Abbott | 12 | $5,261 |
| Medtronic(2 entities) | 39 | $3,920 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $2,580 |
| Atricure, Inc. | 8 | $1,081 |
| Sanofi-aventis U.S. LLC | 6 | $598 |
| Novartis | 52 | $502 |
| Amgen | 20 | $458 |
| AstraZeneca | 12 | $395 |
| Boehringer Ingelheim | 18 | $340 |
| Pfizer | 18 | $306 |
| Biotronik Inc. | 5 | $287 |
| Johnson & Johnson | 8 | $257 |
| Merck | 11 | $223 |
| Vifor Pharma, Inc. | 1 | $200 |
| E.r. Squibb & Sons, L.L.C. | 17 | $191 |
| Novo Nordisk | 8 | $168 |
| Abiomed | 1 | $130 |
| Alnylam Pharmaceuticals Inc. | 4 | $100 |
| Philips North America LLC | 1 | $81 |
| Medicomp Inc | 4 | $77 |
| Esperion Therapeutics, Inc. | 4 | $77 |
| Daiichi Sankyo Inc. | 3 | $73 |
| Biosense Webster, Inc. | 3 | $68 |
| Lexicon Pharmaceuticals, Inc. | 2 | $56 |
| Althera Pharmaceuticals LLC | 2 | $44 |
| Cardiva Medical, Inc. | 2 | $32 |
| Azurity Pharmaceuticals, Inc. | 1 | $25 |
| Bayer | 1 | $22 |
| Akcea Therapeutics, Inc. | 1 | $22 |
| Irhythm Technologies, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Preventice Services, LLC | 1 | $19 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$41,623
- GENERAL - THERAPIES$15,366
- OPTIMIZER SMART SYSTEM$8,082
- Merlin Connectivity and Remote$2,612
- LifeVest$2,500
- Confirm Rx$2,453
- Reveal LINQ$1,045
- Watchman$1,018
- Micra$759
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$545
- MULTAQ$500
- SYNERGY ABLATION SYSTEM$443
- WATCHMAN Access System$381
- ARCTIC FRONT ADVANCE$328
- WATCHMAN FLX$274
- Farapulse$273
- Veltassa$200
- GENERAL - STENTS$150
- VersaCross Access Solution$141
- AURORA EV-ICD MRI SURESCAN$138
How this compares
$74,342 in reported general payments places this provider in the 70th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
See all clinical cardiac electrophysiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 191 | $202,755 |
| XareltoRivaroxaban | 69 | $78,476 |
| Repatha SureclickEvolocumab | 44 | $50,209 |
| EntrestoSacubitril/Valsartan | 25 | $42,553 |
| VascepaIcosapent Ethyl | 13 | $8,923 |
| JardianceEmpagliflozin | 11 | $7,636 |
| Atorvastatin Calcium | 251 | $4,393 |
| Metoprolol Succinate | 244 | $4,084 |
| Rosuvastatin Calcium | 73 | $2,342 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 32 | $2,199 |
| Ezetimibe | 66 | $1,498 |
| Amiodarone Hcl | 91 | $1,441 |
| Losartan Potassium | 96 | $1,391 |
| Amlodipine Besylate | 93 | $1,039 |
| Pantoprazole Sodium | 24 | $956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $306 | $202,755191 claims |
| Johnson & JohnsonXarelto | $257 | $78,47669 claims |
| NovartisEntresto | $502 | $42,55325 claims |
| Boehringer IngelheimJardiance | $340 | $7,63611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
Other clinical cardiac electrophysiology in Philadelphia
- Pasquale SantangeliPhiladelphia$1.3M
- Francis MarchlinskiPhiladelphia$1.2M
- David FrankelPhiladelphia$722K
- Fermin GarciaPhiladelphia$713K
- Timothy MarkmanPhiladelphia$693K
- Ralph VerdinoPhiladelphia$682K
- Robert SchallerPhiladelphia$579K
- Rajat DeoPhiladelphia$519K
- Matthew HymanPhiladelphia$474K
- Joshua CooperPhiladelphia$405K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.